Interest in metabolic medicines is riding high, led by the popular class of weight management drugs known as GLP-1 agonists. BioAge Labs aims to help those medications work better with a lead drug ...
Bioage Labs Inc. is advancing its apelin receptor (APJ) agonist programs for obesity and other indications, and has entered into an option agreement with Jikang Therapeutics to license a novel APJ ...
New composition of matter IP filed for chemically distinct, orally active, and highly potent small molecule APJ agonists EMERYVILLE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (BIOA) ...
Funding to advance Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist, in combination with Lilly’s Zepbound (tirzepatide) and therapeutic pipeline Azelaprag improves metabolic and ...
BioAge Labs, Inc. has announced an option agreement with JiKang Therapeutics to potentially in-license a novel APJ agonist nanobody, enhancing its pipeline for treating obesity and related metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results